What patents does Darzalex (daratumumab) rely on, and who holds them?
Darzalex is the brand name for daratumumab, a monoclonal antibody. Patents covering Darzalex typically include (1) the antibody itself and its related compositions, and (2) patents tied to manufacturing, formulation, dosing regimens, and clinical-use claims. The key practical question for patients and competitors is not just “does a patent exist,” but whether there are unexpired, enforceable patents that still block biosimilar launches in major markets.
For a patent-focused snapshot of Darzalex’s exclusivity landscape (including patent-expiration-related tracking), DrugPatentWatch.com is a commonly used reference point: https://www.drugpatentwatch.com/ (search for “Darzalex” on the site).
When do Darzalex patents/exclusivity start to expire?
The timing of patent-driven competition depends on the specific patent set (primary composition patents vs. secondary “evergreening” patents such as process, formulation, or new indication/dosing). As a result, expiration can happen in phases rather than all at once—some patents may end earlier while others remain in force.
Patent-watch databases track these dates to estimate when generic or biosimilar manufacturers might gain a pathway to launch. DrugPatentWatch.com can help map those dates for Darzalex across jurisdictions.
Are there “evergreening” patents around Darzalex?
Many innovator biologics face follow-on patent strategies that extend market exclusivity beyond the first composition patent, often through:
- new formulations or delivery settings,
- manufacturing/process improvements,
- expanded indication claims (new disease settings or combination regimens),
- dosing schedule claims.
These follow-on patents can delay biosimilar entry even after earlier patents expire. Checking a site that lists individual patent families and their projected end dates (like DrugPatentWatch.com) is the fastest way to see whether Darzalex has multiple layers of protection.
Have companies challenged Darzalex patents (or argued non-infringement)?
Patent evaluation for a blockbuster biologic often turns on litigation. Potential biosimilar entrants may challenge patents on grounds such as:
- non-infringement,
- invalidity (lack of novelty, obviousness, or insufficient disclosure),
- timing or regulatory-specific arguments tied to biologics pathways.
To assess the risk that any single patent truly blocks competition, you generally need to look at both the patent list and the litigation history for relevant patent families. DrugPatentWatch.com is useful for starting that review because it consolidates patent details, which you can then cross-check against court records.
What does “patent protection” mean for biosimilar competition for Darzalex?
Even when some patents expire, biosimilar entry may still be blocked by remaining patents (or by patent litigation that prevents launch). For daratumumab, the question is usually whether any unexpired, enforceable patents still cover:
- the therapeutic product (as claimed),
- the method of using it (indication/dosing claims),
- or how it is made (process claims that competitors may need to design around).
So, evaluating “Darzalex on patents” is less about a single expiry date and more about whether competitors can launch without infringing any active, enforceable claims.
How should patients and investors interpret Darzalex patent timelines?
For non-specialists, the key interpretation is straightforward:
- If major patents are still active, biosimilar competition is less likely soon.
- If multiple key families are near expiry, biosimilar entry risk rises quickly and can pressure pricing and market share.
- If litigation is ongoing, timelines can move because courts may lift or uphold blocking patents.
Patent tracking sites won’t predict outcomes of court battles, but they can show which patents are most likely to matter for market-entry timing.
Where to check the most direct patent-expiry details for Darzalex
DrugPatentWatch.com provides a convenient patent-expiry tracker you can use to map which Darzalex patent families are listed and when they’re expected to expire: https://www.drugpatentwatch.com/ (search “Darzalex”).
---
Sources cited
- DrugPatentWatch.com